169 related articles for article (PubMed ID: 36595778)
1. Impact of iron overload on poor graft function after allo-HSCT in a patient with transfusion-dependent low-risk MDS: A case report and literature review.
Wang C; Zhao M; Nie Y; Yang Y; Tan Y; Du Z; Gao S; Li W
Medicine (Baltimore); 2022 Dec; 101(51):e32012. PubMed ID: 36595778
[TBL] [Abstract][Full Text] [Related]
2. A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation
Cremers EMP; de Witte T; de Wreede L; Eikema DJ; Koster L; van Biezen A; Finke J; Socié G; Beelen D; Maertens J; Nagler A; Kobbe G; Ziagkos D; Itälä-Remes M; Gedde-Dahl T; Sierra J; Niederwieser D; Ljungman P; Beguin Y; Ozkurt ZN; Anagnostopoulos A; Jindra P; Robin M; Kröger N
Leuk Lymphoma; 2019 Oct; 60(10):2404-2414. PubMed ID: 30997844
[TBL] [Abstract][Full Text] [Related]
3. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
4. [Effects of iron chelation therapy on allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome patients with iron overload].
Gu CH; Li CX; Ye L; Liu H; Ma JF; Wang T; Zou Q; Chen J; Chen XC; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):189-93. PubMed ID: 27033754
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.
Alessandrino EP; Della Porta MG; Bacigalupo A; Malcovati L; Angelucci E; Van Lint MT; Falda M; Onida F; Bernardi M; Guidi S; Lucarelli B; Rambaldi A; Cerretti R; Marenco P; Pioltelli P; Pascutto C; Oneto R; Pirolini L; Fanin R; Bosi A
Haematologica; 2010 Mar; 95(3):476-84. PubMed ID: 19903678
[TBL] [Abstract][Full Text] [Related]
6. [The role of iron metabolism in myelodysplastic syndromes].
Finelli C; Clissa C; Stanzani M
Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
[TBL] [Abstract][Full Text] [Related]
7. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Shahzad M; Siddiqui RS; Anwar I; Chaudhary SG; Ali T; Naseem M; Ahmed TF; Ahmed Z; Khurana S; Ahmed N; Balusu R; Singh AK; Hematti P; Callander NS; Abhyankar SH; McGuirk JP; Mushtaq MU
Transplant Cell Ther; 2021 Oct; 27(10):877.e1-877.e8. PubMed ID: 34284148
[TBL] [Abstract][Full Text] [Related]
8. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
9. Iron overload in patients with myelodysplastic syndromes: An updated overview.
Moukalled NM; El Rassi FA; Temraz SN; Taher AT
Cancer; 2018 Oct; 124(20):3979-3989. PubMed ID: 29905937
[TBL] [Abstract][Full Text] [Related]
10. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S
Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020
[TBL] [Abstract][Full Text] [Related]
12. Impact of iron overload in hematopoietic stem cell transplantation.
Wang C; Zhao M; Liu Q; Yang Y; Li Y; Nie Y; Gao S; Li W
Transpl Immunol; 2023 Jun; 78():101820. PubMed ID: 36921731
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
Cazzola M; Della Porta MG; Malcovati L
Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076
[TBL] [Abstract][Full Text] [Related]
14. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
15. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.
Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A
Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730
[TBL] [Abstract][Full Text] [Related]
16. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
17. Iron Overload Following Hematopoietic Stem Cell Transplantation: Prevalence, Severity, and Management in Children and Adolescents with Malignant and Nonmalignant Diseases.
Cattoni A; Capitoli G; Casagranda S; Corti P; Adavastro M; Molinaro A; Di Gennaro F; Bonanomi S; Biondi A; Galimberti S; Balduzzi A
Transplant Cell Ther; 2023 Apr; 29(4):271.e1-271.e12. PubMed ID: 36708803
[TBL] [Abstract][Full Text] [Related]
18. Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation.
Xiao Y; Song J; Jiang Z; Li Y; Gao Y; Xu W; Lu Z; Wang Y; Xiao H
Int J Med Sci; 2014; 11(6):652-7. PubMed ID: 24834012
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
20. European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation.
Chien SH; Liu YC; Liu CJ; Ko PS; Wang HY; Hsiao LT; Lin JS; Chiou TJ; Liu CY; Gau JP
J Chin Med Assoc; 2020 Mar; 83(3):238-244. PubMed ID: 31904659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
